



**CCM DUOPHARMA BIOTECH BERHAD (524271-W)**  
(Incorporated in Malaysia)  
**UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT**  
**FOR THE PERIOD ENDED 30 JUNE 2018**

	<b>30 June 2018</b>	<b>30 June 2017</b>
	<b>RM '000</b>	<b>RM '000</b>
<b>Cash flows from operating activities</b>		
Profit before taxation	26,170	24,764
Adjustments for:		
Depreciation of property, plant and equipment	11,531	11,304
Interest income	(702)	(1,303)
Finance costs	3,072	2,652
<i>Operating profit before changes in working capital</i>	40,071	37,417
Change in inventories	(1,292)	(7,660)
Change in receivables, deposits and prepayments	(56,523)	(34,867)
Change in payables and accruals	17,072	15,413
<i>Cash generated from operations</i>	(672)	10,303
Finance costs paid	(3,072)	(2,652)
Interest income	702	1,303
Income tax paid	(1,991)	(6,702)
<b>Net cash generated from operating activities</b>	(5,033)	2,252
<b>Cash flows from investing activities</b>		
Acquisition of other investment	(59,157)	-
Acquisition of property, plant and equipment	(28,371)	(23,408)
Acquisition of intangible assets	(1,252)	(860)
<b>Net cash used in investing activities</b>	(88,780)	(24,268)
<b>Cash flows from financing activities</b>		
Drawdown of borrowings	84,745	16,265
Repayment of borrowings	(10,000)	(15,000)
Dividends paid to shareholders of the Company	-	(11,158)
<b>Net cash used in financing activities</b>	74,745	(9,893)
Net decrease in cash and cash equivalents	(19,068)	(31,909)
Exchange differences on translation of financial statement of foreign operations	268	12
Cash and cash equivalents at 1 January	96,021	114,814
<b>Cash and cash equivalents as at 30 June</b>	77,221	82,917
	-	-
(l) Cash and cash equivalents comprise:		
	<b>RM '000</b>	<b>RM '000</b>
Cash and bank balances	44,691	28,910
Deposits placed with licensed financial institutions	32,530	54,007
	77,221	82,917

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2017 and the accompanying explanatory notes attached to the interim financial statements.)